Tempus AI's Surge and US Bio Market Trends

Peptron's stock price plummeted as market expectations for a main contract were dashed.

In the past, statements from management and treasury stock purchases sometimes led to a rebound in stock prices.

With a contract with global Big Pharma Eli Lilly remaining an anticipated factor, the company kept open the possibility of a contract through an announcement after the evaluation concluded. Researcher Kang Ha-na explained that the end of the technology evaluation period does not necessarily mean the termination of the contract.

The company sought to alleviate some market concerns by announcing the possibility of a contract after the evaluation ended.

A contract with global Big Pharma Eli Lilly remains an anticipated factor.

Researcher Kang Ha-na stated that when US biotechs release data that falls short of expectations, their stock prices tend to plummet by 30-40%.

The market maintains a very critical view of loss-making biotechs, with increasing importance placed on clear deals and clinical data rather than mere expectations.

Big Pharma companies are actively pursuing M&A and technology transfers to counter pipeline patent expirations.

Although a Dutch court ruled that Merck's Keytruda SC infringed on Halozyme's patent, experts analyzed it as a matter that would be settled through agreement, given its already commercialized status.

Consequently, it was anticipated that the practical impact on Alteogen would not be substantial.

Instead of the entire bio sector rising simultaneously as in the past, a strong individual stock tendency is emerging, where stock prices move according to the performance of individual companies.

It is difficult for stock prices to rise based on vague expectations alone; clinical data verification, response to patent cliffs, and AI-based infrastructure are key investment factors.

Moderna is a company that has consistently invested in AI even before the COVID-19 pandemic.

mRNA cancer vaccines tend to maximize their effectiveness when administered in combination with existing cancer drugs like Keytruda.

Moderna's strategic investments continue to align with the patent expiration period of Big Pharma companies.

This candidate substance, which secured a 3 trillion won contract with Roche and Genentech and received a 280 billion won upfront payment, aims to prevent muscle loss and preserve muscle. Hanmi Pharmaceutical's UCN2 is involved in fat cell decomposition and skeletal muscle formation, demonstrating its market potential.

This peptide has a mechanism that promotes lipolysis in fat cells and participates in skeletal muscle formation.

Hanmi Pharmaceutical had previously signed a 3 trillion won contract with Roche and Genentech for UCN2, receiving an upfront payment of 280 billion won.

The vast clinical records accumulated through genomic testing and tissue and blood analysis of cancer patients represent Tempus AI's unique competitive advantage.

These proprietary genomic tests, drug response, survival rates, and recurrence data are the fundamental reasons why Big Pharma companies collaborate with AI firms.

Even when Moderna previously released mRNA cancer vaccine data, Tempus AI's stock price increased by 24%.

Tempus AI already maintained existing contractual relationships with Moderna and several other Big Pharma companies.

The OneQ US Medical AI is similar to the domestic version of ARKG, while the KoAct US Bio Healthcare Active has a similar nature to the domestic version of IBB.

Active ETFs tend to focus investments on specific sectors rather than diversified investment.

Revenue can be generated repeatedly throughout the new drug development process, from data collection, design, clinical trials, to re-supplementation.

Data-driven companies may have faster monetization speeds even before new drug launch compared to traditional bio companies.

A synergistic structure where Google provides intelligence, Moderna handles design, and Tempus AI manages diagnostics creates this virtuous cycle.

This fund redefined its identity by reorganizing its composition around precision medicine and AI new drug related companies.

This change in stock composition is interpreted as further clarifying the ETF's identity as 'spicy.'

It can be confirmed that the weights of Illumina and Moderna have been adjusted.

AIKG has the highest 'spicy' index, followed by OneQ US Medical AI, and then KoAct US Bio IBB.

ARKG has a high proportion of genomics companies, OneQ US Medical AI focuses on diagnosis and new drug development processes, and KoAct US Bio Healthcare may have higher volatility due to M&A candidate scouting.

For conservative investors, approaching IBB or KoAct US Bio Healthcare ETFs is recommended.

It is possible to adopt a strategy of consistently holding an index-tracking ETF within the sector as a core portfolio.

In addition, ETFs in high-growth areas like AI new drug development can be used as satellites to pursue additional returns, and a strategy of adjusting the overall bio proportion to ratios such as 6:4 or 7:3 can also be considered.

The end of the year is a difficult time to predict next year's leading stocks, so it's best to build a diversified portfolio with stocks that are affordable, perform well, and have strong fundamentals and momentum.

Investing in various sectors with stocks that haven't yet risen but have growth potential for the next year can allow for comfortable long-term investing.

Utilizing ETFs that include representative stocks from specific sub-sectors can be an effective method for diversified investment.